Facebook
Twitter
LinkedIn
Forward
Advances in Influenza Treatment: Optimizing Outcomes in Risk Influenza Patients with Cardiometabolic Conditions
Despite advances in understanding, prevention, and treatment, influenza is still associated with a constant public health concern. Moreover, in patients with chronic conditions, including those with diabetes, cardiovascular disease, renal impairment, or with cardiometabolic risk factors (obesity, tobacco users), influenza can often lead to severe or even fatal disease. Vaccination against the influenza virus is one of the most effective ways to decrease the impact of influenza in individuals with the cardiometabolic disease but due to frequent viral shifts, existing vaccines may be rendered ineffective and new vaccine formulations are only available after the emergence and spread of an existing influenza pandemic, which significantly decreases their utility. Furthermore, the effectiveness of influenza vaccines is reduced in elderly individuals (who usually have a high cardiometabolic burden) and in those with diabetes or other chronic health conditions.
Given that patients with diabetes, heart disease, obesity, or other cardiometabolic risk factors are at a high-risk for developing flu-related complications, it is important for clinicians that care for these patients to be aware of the impact of influenza. This webinar, led by 3 experts in the field, will address the latest evidence in influenza treatment and management of patients with chronic cardiometabolic health conditions.
Target Audience
This activity is designed for US-based endocrinologists, cardiologists, physician assistants, registered nurses, nurse practitioners, and pharmacists.
Learning Objectives
After completing this activity, the participant should be better able to:
- Summarize the influenza life cycle and the clinical impacts of influenza in patients with chronic cardiometabolic conditions
- Interpret existing and new evidence with traditional and new influenza treatments for high-risk patients, including differences in efficacy, safety, and mechanisms of action
- Identify approaches to reducing the burden of influenza in cardiometabolic patients, including prompt treatment with antivirals or referrals
Additional Information
Stefan Gravenstein, MD, MPH
Director of the Division of Geriatrics and Palliative Medicine
Department of Medicine
Warren Alpert Medical School of Brown University
Providence, RI
Dr. Gravenstein discloses the following:
Consulting Fees: Janssen, Seqirus, Sanofi
Contracted Research: Seqirus, Sanofi, Pfizer
Michael G. Ison, MD, MS, FIDSA, FAST
Division of Infectious Diseases and Organ Transplantation
Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Chicago, IL
Dr. Ison discloses the following:
Research Support (Paid to Northwestern University): AiCuris, Genentech/Roche, Janssen, Shire
Paid Consultation (Paid to Michael Ison): AlloVir, Celltrion, Genentech/Roche, Janssen, Shionogi, Viracor Eurofins
Unpaid Consultation: GlaxoSmithKlein, Romark, Vertex
Data and Safety Monitoring Board Participation: NIH, Janssen, Merck, Vitaeris
Gregory A. Poland, MD, MACP, FRCP
Mary Lowell Leary Emeritus Professor of Medicine
Distinguished Investigator, Mayo Clinic
Director, Mayo Vaccine Research Group
Editor-in-Chief, VACCINE
Mayo Clinic
Rochester, MN
Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc., Avianax, Adjuvance, Sanofi Pasteur, GlaxoSmithKline, Emergent Biosolutions, Medicago, and Dynavax. Dr. Poland holds two patents related to vaccinia and measles peptide research. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies.
Planners and Managers Disclosures
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.
Conflict of Interest Disclosure Policies
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This activity is jointly provided by Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and CMHC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA PRA Category 1 Credit(s)™
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Contact Hour(s)
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.50 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.
CE for Pharmacists
Postgraduate Institute for Medicine designates this continuing education activity for 1.50 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
This is an application-based activity. Universal Activity Number (UAN): JA4008162-9999-20-2150-H01-P
Available Credit
- 1.50 AMA PRA Category 1 Credit™
This course is offered through MyCME. To take this course you will be redirected to MyCME's website. You must have an account with MyCME in order to complete this activity.
MOCINGBIRD continues to work with our CME partner network to provide courses directly to you. We appreciate your patience as we work toward that goal!